



Bibliography of Medication Compliance

**implications of medication noncompliance
publications sorted by therapeutic areas**

Maintained by ISPOR Medication Compliance Bibliography Group

Table of Contents

Peer-reviewed papers..... 3

Review articles 10

Books 13

Book chapters 13

Abstracts from conference/symposium/workshop 14

Newsletters, editorials, commentaries, special reports..... 15

Websites 15

Others 15

Contact us 16

Peer-reviewed papers

1. Arthritis/osteoporosis/musculoskeletal disorders

De Klerk E, van der Linden SJ. Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device. *Br J Rheumatol* 1996; 35(1):60-65.

2. Cancer

Khalil AA, Bentzen SM, Bernier J, Saunders MI, Horiot JC, Van Den BW et al. Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. *Int J Radiat Oncol Biol Phys* 2003; 55(3):568-575.

Foucar K, Duncan MH, Stidley CA, Wiggins CL, Hunt WC, Key CR. Survival of children and adolescents with acute lymphoid leukemia. A study of American Indians and Hispanic and non-Hispanic whites treated in New Mexico (1969 to 1986). *Cancer* 1991; 67(8):2125-2130.

Phipps S, DeCuir-Walley S. Adherence issues in pediatric bone marrow transplantation. *J Ped Psychol* 1990; 15:459-475.

Richardson JL, Shelton DR, Krailo M, Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. *J Clin Oncol* 1990; 8(2):356-364.

Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: A comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. *Ann Intern Med* 1987; 160:7-12.

Pizzo PA, Robichaud KJ, Edwards BK, Schumaker C, Kramer BS, Johnson A. Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial. *J Pediatr* 1983; 102(1):125-133.

3. Cardiovascular diseases/disorders (including smoking, obesity & stroke)

Ongtengco I, Morales D, Sanderson J, Lu ZR, Beilin LJ, Burke V et al. Persistence of the antihypertensive efficacy of amlodipine and nifedipine GITS after two 'missed doses': a randomised, double-blind comparative trial in Asian patients. *J Hum Hypertens* 2002; 16(11):805-813.

Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. *Heart* 2002; 88(3):229-233.

Nuesch R, Schroeder K, Dieterle T, Martina B, Battegay E. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. *BMJ* 2001; 323(7305):142-146.

Dew MA, Kormos RL, Roth LH, Murali S, DiMartini A, Griffith BP. Early post-transplant medical

compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. *J Heart Lung Transplant* 1999; 18(6):549-562.

Irvine J, Baker B, Smith J, Jandciu S, Paquette M, Cairns J et al. Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. *Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Psychosom Med* 1999; 61(4):566-575.

De Geest S, Abraham I, Moons P, Vandeputte M, Van Cleemput J, Evers G et al. Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. *J Heart Lung Transplant* 1998; 17(9):854-863.

Mounier-Vehier C, Bernaud C, Carre A, Lequeuche B, Hotton JM, Charpentier JC. Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. *Am J Hypertens* 1998; 11(4 Pt 1):478-486.

McCrinkle BW, O'Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. *J Pediatr* 1997; 130(2):266-273.

Morrell RW, Park DC, Kidder DP, Martin M. Adherence to antihypertensive medications across the life span. *Gerontologist* 1997; 37(5):609-619.

van der Meer FJ, Briet E, Vandenbroucke JP, Sramek DI, Versluijs MH, Rosendaal FR. The role of compliance as a cause of instability in oral anticoagulant therapy. *Br J Haematol* 1997; 98(4):893-900.

Rich MW, Gray DB, Beckham V, Wittenberg C, Luther P. Effect of a multidisciplinary intervention on medication compliance in elderly patients with congestive heart failure. *Am J Med* 1996; 101(3):270-276.

Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. *Am J Med* 1996; 100(2):197-204.

Jacobson TA, Chin MM, Curry CL, Miller V, Papademetriou V, Schlant RC et al. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. *Arch Intern Med* 1995; 155(17):1900-1906.

Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study. *Arch Intern Med* 1994; 154(23):2649-2657.

Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. *Journal of the American Medical Association* 1993; 270(6):742-744.

Schectman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium, and lovastatin) for treating hypercholesterolemia in veterans. *Am J Cardiol* 1993; 71:759-765.

Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ et al. Treatment adherence

and risk of death after a myocardial infarction. *Lancet* 1990; 336(8714):542-545.

Reis GJ, Boucher TM, Sipperly ME, Silverman DI, McCabe CH, Baim DS et al. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. *Lancet* 1989; 2(8656):177-181.

Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care* 1986; 24:67-74.

Hoeg JM, Maher MB, Bou E, Zech LA, Bailey KR, Gregg RE et al. Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin. *Circulation* 1984; 70(6):1004-1011.

Widmer RB, Cadoret RJ, Troughton E. Compliance characteristics of 291 hypertensive patients from a rural midwest area. *J Fam Pract* 1983; 17(4):619-625.

4. Diabetes/metabolic disorder

<NONE>

5. Eye & skin diseases/disorders

Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? *Am J Ophthalmol* 1986; 101:524-530.

Granstrom PA. Progression of visual field defects in glaucoma. Relation to compliance with pilocarpine therapy. *Arch Ophthalmol* 1985; 103(4):529-531.

6. Infection

Guaraldi G, Murri R, Orlando G, Orlandi E, Sterrantino G, Borderi M et al. Morphologic Alterations in HIV-Infected People with Lipodystrophy Are Associated with Good Adherence to HAART. *HIV Clin Trials* 2003; 4(2):99-106.

Samman Y, Krayem A, Haidar M, Mimesh S, Osoba A, Al Mowaallad A et al. Treatment outcome of tuberculosis among Saudi nationals: role of drug resistance and compliance. *Clin Microbiol Infect* 2003; 9(4):289-294.

Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo AL et al. Relationship between HAART adherence and adipose tissue alterations. *J Acquir Immune Defic Syndr* 2002; 31 Suppl 3:S140-4.:S140-S144.

Cohn SE, Kammann E, Williams P, Currier JS, Chesney MA. Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in Acquired Immunodeficiency

Syndrome. *Clin Infect Dis* 2002; 34(8):1129-1136.

Flandre P, Peytavin G, Meiffredy V, Saidi Y, Descamps D, Delagnes M et al. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. *Antivir Ther* 2002; 7(2):113-121.

Garcia dO, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. *J Acquir Immune Defic Syndr* 2002; 30(1):105-110.

Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. *AIDS* 2002; 16(7):1051-1058.

Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. *AIDS* 2002; 16(16):2175-2182.

Ickovics JR, Cameron A, Zackin R, Bassett R, Chesney M, Johnson VA et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. *Antivir Ther* 2002; 7(3):185-193.

Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. *Clin Infect Dis* 2002; 34(8):1115-1121.

McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterology* 2002; 123(4):1061-1069.

Raboud JM, Harris M, Rae S, Montaner JS. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. *HIV Med* 2002; 3(2):118-124.

Van Vaerenbergh K, De Geest S, Derdelinckx I, Bobbaers H, Carbonez A, Deschamps A et al. A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure. *Antivir Chem Chemother* 2002; 13(4):231-240.

Brigido LF, Rodrigues R, Casseb J, Oliveira D, Rossetti M, Menezes P et al. Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. *AIDS Patient Care STDS* 2001; 15(11):587-593.

DeMasi RA, Graham NM, Tolson JM, Pham SV, Capuano GA, Fisher RL et al. Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. *Adv Ther* 2001; 18(4):163-173.

Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. *AIDS* 2001; 15(16):2109-2117.

- McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. *Clin Infect Dis* 2001; 33(5):700-705.
- Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. *Arch Intern Med* 2001; 161(16):1962-1968.
- Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. *AIDS* 2000; 14(4):357-366.
- Giron-Gonzalez JA, Lopez-Sanchez A, Elvira J, Perez E, Fernandez-Gutierrez C. Effect of patient adherence to antiretroviral therapy on CD4+ cell count, HIV-1 RNA, and serum concentrations of tumor necrosis factor and its soluble receptors. *Eur J Clin Microbiol Infect Dis* 2000; 19(11):852-858.
- Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med* 2000; 133(1):21-30.
- Bachmann LH, Stephens J, Richey CM, Hook EW, III. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. *Sex Transm Dis* 1999; 26(5):272-278.
- Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. *AIDS* 1999; 13(9):1099-1107.
- Maher K, Klimas N, Fletcher MA, Cohen V, Maggio CM, Triplett J et al. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an Urban Veterans Affairs Medical Center. *J Acquir Immune Defic Syndr* 1999; 22(4):358-363.
- d'Arminio MA, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. *AIDS* 1998; 12(13):1631-1637.
- Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. *Chest* 1997; 111(5):1168-1173.
- Anastasio GD, Little JM, Jr., Robinson MD, Pettice YL, Leitch BB, Norton HJ. Impact of compliance and side effects on the clinical outcome of patients treated with oral erythromycin. *Pharmacotherapy* 1994; 14(2):229-234.
- Browning GG, Gatehouse S, Calder IT. Medical management of active chronic otitis media: A controlled study. *J Laryngol Otol* 1988; 102:491-495.

Macknin ML, Jones PK. Oral dexamethasone for treatment of persistent middle ear effusion. *Pediatrics* 1985; 75:329-335.

Reed BD, Lutz LJ, Zazove P, Ratcliffe SD. Compliance with acute otitis media treatment. *J Fam Pract* 1984; 19(5):627-632.

Schwartz RH, Puglise J, Rodriguez WJ. Sulphamethoxazole prophylaxis in the otitis-prone child. *Arch Dis Child* 1982; 57:590-593.

7. Gastrointestinal diseases/disorders

Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. *Am J Med* 2003; 114(1):39-43.

Wermeille J, Cunningham M, Dederding JP, Girard L, Baumann R, Zelger G et al. Failure of *Helicobacter pylori* eradication: is poor compliance the main cause? *Gastroenterol Clin Biol* 2002; 26(3):216-219.

Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas A et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. *Gut* 1997; 40(4):485-491.

Dohil R, Israel DM, Hassall E. Effective 2-week therapy for *Helicobacter pylori* disease in children. *Am J Gastroenterol* 1997; 92:244-247.

Cutler AF, Schubert TT. Patient factors affecting *Helicobacter pylori* eradication with triple therapy. *Am J Gastroenterol* 1993; 88:505-509.

Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ, Jr., Klein PD et al. Factors influencing the eradication of *Helicobacter pylori* with triple therapy. *Gastroenterology* 1992; 102(2):493-496.

Rappaport L, Landman G, Fenton T, Levine MD. Locus of control as predictor of compliance and outcome in treatment of encopresis. *J Pediatr* 1986; 109(6):1061-1064.

8. Mental health

Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. *Schizophr Res* 2002; 54(3):253-264.

Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. *Am J Psychiatry* 2002; 159(11):1927-1929.

Demyttenaere K, Mesters P, Boulanger B, Dewe W, Delsemme MH, Gregoire J et al. Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine. *J Affect Disord* 2001;

65(3):243-252.

Thompson C, Peveler RC, Stephenson D, McKendrick J. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: A randomized comparison of fluoxetine and a tricyclic antidepressant. *American Journal of Psychiatry* 2000; 157(3):338-343.

Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. *Acta Psychiatrica Scand* 2000; 102(3):203-210.

Verghese A, John JK, Rajkumar S, Richard J, Sethi BB, Trivedi JK. Factors associated with the course and outcome of schizophrenia in India. Results of a two-year multicentre follow-up study. *Br J Psychiatry* 1989; 154:499-503.:499-503.

Connelly CE, Davenport YB, Nurnberger JI, Jr. Adherence to treatment regimen in a lithium carbonate clinic. *Arch Gen Psychiatry* 1982; 39(5):585-588.

9. Neurological diseases/disorders & pain

Lutz RW, Silbret M, Olshan N. Treatment outcome and compliance with therapeutic regimens: long-term follow-up of a multidisciplinary pain program. *Pain* 1983; 17(3):301-308.

10. Other diseases/disorders

Billups SJ, Malone DC, Carter BL. The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. *Pharmacotherapy* 2000; 20(8):941-949.

Hays RD, Kravitz RL, Mazel RM, Sherbourne CD, DiMatteo MR, Rogers WH et al. The impact of patient adherence on health outcomes for patients with chronic disease in the Medical Outcomes Study. *J Behav Med* 1994; 17(4):347-360.

Wright DD, Franks PJ, Blair SD, Backhouse CM, Moffatt C, McCollum CN. Oxerutins in the prevention of recurrence in chronic venous ulceration: randomized controlled trial. *Br J Surg* 1991; 78(10):1269-1270.

Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. *Transplantation* 1990; 49(2):374-377.

11. Respiratory diseases/disorders

Dasgupta R, Guest JF. Factors Affecting UK Primary-Care Costs of Managing Patients with Asthma over 5 Years. *Pharmacoeconomics* 2003; 21(5):357-369.

Soussan D, Liard R, Zureik M, Touron D, Rogeaux Y, Neukirch F. Treatment compliance, passive

smoking, and asthma control: a three year cohort study. *Arch Dis Child* 2003; 88(3):229-233.

Balkrishnan R, Christensen DB. Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. *Clin Ther* 2000; 22(4):452-469.

Jonasson G, Carlsen KH, Sodal A, Jonasson C, Mowinckel P. Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma. *Eur Respir J* 1999; 14(1):150-154.

van Ganse E, Hubloue I, Vincken W, Leufkens HG, Gregoire J, Ernst P. Actual use of inhaled corticosteroids and risk of hospitalisation: a case-control study. *Eur J Clin Pharmacol* 1997; 51(6):449-454.

Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. *J Allergy Clin Immunol* 1996; 98(6 Pt 1):1051-1057.

12. Urinary & kidney diseases/disorders

De Geest S, Borgermans L, Gemoets H, Abraham I, Vlaminck H, Evers G et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. *Transplantation* 1995; 59(3):340-347.

Hilbrands LB, Hoitsma AJ, Koene RAP. Medication compliance after renal transplantation. *Transplantation* 1995; 60:914-920.

13. Women's & Men's health

<NONE>

Review articles

1. Arthritis/osteoporosis/musculoskeletal disorders

No articles identified.

2. Cancer

Urquhart J. Patient compliance with crucial drug regimens: implications for prostate cancer. *Eur Urol* 1996;29 Suppl 2:124-31.

3. Cardiovascular diseases/disorders (including smoking, obesity & stroke)

Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. *Heart*. 2002 Aug;88(2):203-6.

Girvin B, Johnston GD. The implications of noncompliance with antihypertensive medication. *Drugs*. 1996 Aug;52(2):186-95.

McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. *Arch Intern Med*. 1997 Sep 22;157(17):1921-9.

Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. *Am Heart J* 1995;130:572-9.

Rudd P. Partial compliance: implications for clinical practice. *J Cardiovasc Pharmacol*. 1993;22 Suppl A:S1-5.

Urquhart J. Partial compliance in cardiovascular disease: risk implications. *Br J Clin Pract Suppl*. 1994 May;73:2-12.

Williams GH. Assessing patient wellness: new perspectives on quality of life and compliance. *Am J Hypertens*. 1998 Nov;11(11 Pt 2):186S-191S.

4. Diabetes/metabolic disorder

No articles identified.

5. Eye & skin diseases/disorders

No articles identified.

6. Infection

Miller LG, Hays RD. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. *AIDS Read* 2000;10(3):177-85.

Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, Bellocchi MC, Trotta MP, Piano P, Forbici F, Scasso A, Vullo V, d'Arminio Monforte A, Antinori A; AdICoNA Study Group. Virologic correlates of adherence to antiretroviral medications and therapeutic failure. *J Acquir Immune Defic Syndr*. 2002 Dec 15;31 Suppl 3:S118-22.

Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. *J Acquir Immune Defic Syndr*. 2002 Dec 15;31 Suppl 3:S112-7.

7. Gastrointestinal diseases/disorders

Kane S. Patient compliance and outcomes. *Inflamm Bowel Dis*. 1999 May;5(2):134-7.

8. Mental health

Demyttenaere K, Haddad P. Compliance with antidepressant therapy and antidepressant discontinuation symptoms. *Acta Psychiatr Scand Suppl.* 2000;403:50-6.

9. Neurological diseases/disorders & pain

Garnett WR. Antiepileptic drug treatment: outcomes and adherence. *Pharmacotherapy.* 2000 Aug;20(8 Pt 2):191S-199S.

Pledger GW. Compliance in clinical trials: impact on design, analysis and interpretation. *Epilepsy Res Suppl.* 1988;1:125-33.

Turk DC, Rudy TE. Neglected topics in the treatment of chronic pain patients--relapse, noncompliance, and adherence enhancement. *Pain.* 1991 Jan;44(1):5-28.

10. Other diseases/disorders – **includes reviews of all conditions/multiple conditions/general health**

Epstein LH. The direct effects of compliance on health outcome. *Health Psychol* 1984;3(4):385-93.

Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. *Arch Intern Med.* 1993 Aug 23;153(16):1863-8.

Kardas P. [Patient non-compliance as a cause of treatment failure]. *Pol Merkuriusz Lek.* 2000 Oct;9(52):732-5. Article in Polish.

Matsui DM. Drug compliance in pediatrics. Clinical and research issues. *Pediatr Clin North Am.* 1997 Feb;44(1):1-14.

Urquhart J. Erratic patient compliance with prescribed drug regimens: target for drug delivery systems. *Clin Pharmacol Ther.* 2000 Apr;67(4):331-4.

11. Respiratory diseases/disorders

Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? *Ann Allergy Asthma Immunol.* 1997 Sep;79(3):177-85.

Ramsey SD. Suboptimal medical therapy in COPD: exploring the causes and consequences. *Chest.* 2000 Feb;117(2 Suppl):33S-7S.

Rand CS, Wise RA. Measuring adherence to asthma medication regimens. *Am J Respir Crit Care Med* 1994;149(2 Pt 2):S69-76; discussion S77-8.

12. Urinary & kidney diseases/disorders

Leaderbach-Hofmann K, Bunzel B. Noncompliance in organ transplant recipients: a literature review. *Gen Hosp Psychiatry* 2000; 22: 412-24.

13. Women's & Men's health

No articles identified.

Books

Book chapters

Abstracts from conference/symposium/workshop

Newsletters, editorials, commentaries, special reports

Websites

Others

Contact us

ISPOR Medication Compliance

Joyce A. Cramer
Associate Research Scientist
Department of Psychiatry
Yale University
School of
950 Campbell Ave. (G7E)
West Haven, CT 06516-2770
Tel: 203-937-3894
Fax: 203-937-3468
e-mail: joyce.cramer@yale.edu

**ISPOR Medication Compliance
Bibliography Group**

Jasmanda H. Wu
Associate Director, Outcomes Research
Ortho-McNeil Janssen Scientific Affairs, L.L.C.
1125 Trenton-Harbourton Road
Titusville, NJ 08560-0200
Tel: 609-730-7718
Fax: 609-730-2411
e-mail: jwu2@omjus.jnj.com

Sue Capon
Staff Liaison to
Special Interest Groups
ISPOR
Tel: 609-219-0773, ext. 21
e-mail: scapon@ispor.org